Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

12th World AIDS Conference

control * C6te 41

SKeyword

Abstract -

-Keyword

Abstract
ry cats/A prospective, controlled study to evaluate the effect of a

11236

RS 070): A randomized trial to evaluate the efficacy and 12227
articipation in a placebo trial -The PENTA I trial/Parent 12261
orked/An HIV outbreak - A multi-faceted community a 13409
on trial: A randomized, trial of a risk reduction intervent 14273
analysis of randomized trials/Isoniazid prophylaxis fort 451*/22124
patients/Randomized, phase II trial of S.C. interleukin- 22420
ositive patient: Placebo trial of methylphenidate and pe 22429
ymptoms/Randomized trial of an innovative coping inte 22458
A double-blind placebo clinical trial/Thalidomide as a tr 32247
crease adherence in a trial of quadruple-drug therapy i 32364
ptability study of female methods of protection against 33130
a randomized, placebo phase I HIV-1 vaccine trial in U 33219
V testers"/Randomised trial to evaluate an HIV test-cou 33270
n a high risk setting/A trial of condom provision and h 33383
persons living with HIV for disease staging in Vancouv 42284
s/Double blind placebo trial of oral dehydroepiandroste 42326
icipation in a medically heroin prescription program/R 43302
ne data/A randomised trial of a small-group behaviour 43311
ng females sex workers in STD clinic/Knowledge attitu 43358
acy trials/Randomized, evaluation of a prototype infor 43544
cing the challenges of a environment in New York State 44198
subjects/The effects of ethanol ingestion on HIV RNA I 60159
patitis B and C infection in a Swiss prison for women ov 60493
cells in seronegative controls /Increased expression of chemok 21119
mpared to HIV-negative /Syphilis in HIV infection compar 22202
+ individuals and HIV- with and without progressive mult 32210
s and HIV-seronegative /Cytokine and chemokine produc 60787
ction in children is still a controversial issue/Diagnosis of HIV infe 32448
phyria cutanea tarda: A association with HIV infectio 60883
rophylaxis: Community controversies in San Francisco/Post-exp 251*/33179
unselling and testing for convicted people in Buenos Aires, Argenti 43415
erapy: 21 patients from Cook County Hospital, Chicago/Ritonavir 60619
eusing previously-used cookers, cottons, and rinse water and over 60349
s to create strategies to cope with AIDS/The challenge of partners 13429: Helping organizations with AIDS-related loss/Grief at work: 545*/24243
ry"/Helping children to with illness or death in the family, by i 24298
How has the household coped? -A Nigerian case study/HIV/AIDS 34170
ria: How has the media?/Problems of communicating HIV/ 34225
sitive bank employee/ Coping with HIV/AIDS as an elite in the wo 13467
n HIV positive patients/ style is associated with mood and 14173
rom a qualitative study/ with HIV/AIDS: Results from a qua 24255
en living with HIV/AIDS/ and control: Variation and relation 24305
ns living with HIV/AIDS/ skills: The effectiveness of one-da 24351
ho-social reactions and coping strategies of patients with HIV/AID 12455
University of Brasilia in with the AIDS epidemic in the Fede 13484
upport, pessimism, and /Quality of life (QOL) in HIV infectio 14353
ed trial of an innovative intervention for HIV-positive individ 22458
r, Ethiopia/Caring and strategies of families living with TB 24212
nxiety, depression, and among HIV+ adolescents/Life stre 24224
DS caregivers: Test of a support model/Work-related stres 24300
e: Understandings and mechanisms learned during HIV pr 24302
ence and strategies for /Long-term HIV health care profes 24312
group and strategies of with HIV +ve patients/Support gro 24318
on quality of life, mood, and CD4 levels/Effects of self-man 42371
Personal experience in with HIV/Personal experience in 60123
ew medications change with HIV and AIDS?/Do new medi 60609
oop of HIV-1 subtype E/ Coreceptor use and MT2 tropism of HIV-1 11113
rved envelope residue/ utilization by divergent human 11115
rimary HIV-2 isolates/ usage by primary HIV-2 isolat 60683
deletion allele of CCR5 coreceptor gene in HIV infected and norm 11108
hild transmission/HIV-1 usage and CCR5 defective all 60834
C and CXC chemokine coreceptors in vivo correlates with HIV-1 8*/21134
ne/Inactivation of HIV-1 by intrakine/Inactivation of H 41242
HPG)/Evaluation of the corneal endothelium in rabbits treated with 11237
f AIDS cases through coroner services in S.o Paulo/lnvestigati 43457
he medical and infantry corps of the Nigerian Army/Comparison of 43388
AIDS education among corpus-based adolescents/Barriers to eff 13537
-49 years diagnosed in correctional facilities, US, 1993-1996/Ch 13265
nd needle distribution in centres in Ontario, Canada/I 43400
n: CDC's experience in health care/Intervening amo 43408
experience/A model for corrections and community health: A Can 43404
al study/Public health/ collaborations in the preventi 43405
se inhibitors and use of corticoids ointment/"Buffalo Hump" asso 12403
ed tuberculosis: Role of corticosteroids /Severe inflammatory rea 22130
cetate therapy/Severe cortisol deficiency related to high dose me 60367

uth/Using the Internet: Cost-effective way to expand AIDS preve 13342
ounselling programme/ model for developing a blo 33271
ased nursing care: The cost-effective way/Home based nursing c 483*/22466
he Caribbean (LAC): A strategy/Ensuring blood sa 33204

Tanzania and Kenya is
nsive, wide, global and
f pregnant women: Is it
ral therapy (HAART) is
n sub-Saharan Africa/
ntion for runaway youth/
ns in HIV-infected men/
f protease inhibitors/
g among blood-donors/
HIV and managed care:
uation Working Group/
n developing countries/
ng: A decision analysis/
en in rural South Africa:
ng/Breast or bottle? A
opment of standards for
m complex in AIDS/The
atients? Insights from a
on programs in the US/
Iling and testing study/
al (project RESPECT)/
esults from Cameroon/
or the HIV/AIDS care/
icacy of anti-HIV drugs/
r the European patient/
on modeling approach/: Results from the voluntary 580*/33277
/Publishing AIDS/STD Mexi 34379
in England? Study for the E 43134
compared to delayed treat 44243
Cost-effectiveness of isoniazid preventiv 450*/13278
of an intervention for r 14272
of screening for anal s 22307
of protease inhibitors/ 24125
of pooling blood samp 33201
of an interdisciplinary 42417
of primary HIV-preve 43220
of antiretroviral therap 43492
of partner notification 44248
cost-effectiveness and capacity/Antiretr 23297
evaluation of formula f 316*/24124
preventive approache 43537
of prophylaxis for Myc 479*/44238
evaluation/Should pla 44242

Cost comparison of alternatively structure
to clients and willingness to pay for HI
of preventing HIV via counselling: Re
effectiveness of a HIV/AIDS peer edu
and quality indicators for the analysis
and efficacy of anti-HIV drugs/
of HIV infection for the European pati
effectiveness of national investment f

13288
24135
33263
578*/33592
42217
42254
44214
44246
75*/12405

ncreased access at low cost in Burkina Faso/Care and treatment:

se of the AZT-treatment /Method to decrease of the AZT-treat 12438
S: Results from the HIV and services utilization study (HCSU 13229
86-2002. Medical care estimates of HIV/AIDS patient/Estim 13469
phylaxis result in further savings by decreasing utilization of di 22369
e community level/The of HIV treatment and care at the com 24130
Canada: Utilisation and /Antiretroviral therapy in Ontario, Can 24131
AIDS/Incremental drug and survival between two antiretrovir 24134
-patients/Documented saving with low dose filgrastim for HIV 32147
the Internet at minimal: A guide for ASOs based on experien 33474
n clinical outcomes and in a university-based HIV/AIDS progr 42211
e world, one hope: The of making antiretroviral therapy availa 444*/42283
aid population/Use and of alternative therapies in an HIV-infe 42387
te d'lvoire/Minimizing of decentralization of care to AIDS/HI 43519
nd minorities/Impact of saving strategies for access to pharm 44253
Itisite comparison/The of delivering a cognitive-behavioral HI 60215
ng with HIV/AIDS/Low protein diet for people living with HIV/ 60217
erapy/Potential use of of treatment and quality of life data for 60435
gnosticated in 1993, in Costa Rica/Determination of the surviving 13400
national AIDS survey in Rica, 1997/CAP national AIDS surv 23435
STD/HIV prevention in Rica/Bio-psychology and social car 43368
S affected population in Rica wins constitutional challenge/ 536*/44104
S and human rights: The Rican experience/HIV/AIDS and hu 60009
s in female prostitutes, Rica, 1997/Comparison study betw 60329
h and low risk women in Rica, 1997/HIV seroprevalence am 60332
V infection in Morocco/ Costeffectiveness of the strategies for dia 60039
nfected by HIV/CD28 costimulation increases virus replication i 60407
omic research initiative/ Costing HIV/AIDS: The Canadian HIV/AI 480*/24122
bservation database/ HIV using an observation databas 477*/24127
Nairobi, Kenya in 1997/ Costs of care for HIV-positive and HIV-neg 42446
ortality and health care costs for 6,297 AIDS patients in California 441*/12264
suring the net hospital and physician billings for the last thr 24121
omparative health care in a regional HIV/AIDS population/C 24126
alth status and hospital in a French cohort of HIV infected pa 24133
can result in lower total -3 year analysis/Recent advances i 24136
d translate to increased?/The CMA experience: Applying co 32405
ogram/Pharmaceutical associated with managing a populati 33191
ma: Inputs, outputs, unit, coverage, behavioural impact and b 33519
/Translating perceived of volunteerism into personal and col 34147
he economic and social from the HIV/AIDS epidemic in Colo 34150
d testing on outcomes, and patterns of therapy/Impact of dr 42173
s of care and estimated at an urban medical center during th 442*/42430
-1996/Analysis of unit in 23 condom social marketing progr 467*/44240
preliminary analysis of in Brazil/One day clinic (ODC) servi 44255
- How does it affect the for HIV care?/New principals for tre 60546
d healthcare utilization with increased use of protease inhibi 60578
patients in the interior of C6te d'lvoire/Distribution of HIV-1 subtype 11182
utopsy data in Abidjan, d'lvoire/Clinical manifestations of ad 12146
ban antenatal clinics in d'lvoire, 1997/Prevalence of HIV and 13111
sis patients in Abidjan, d'lvoire/HIV-1 RNA plasma viral load 13271
V-2 infections, Abidjan, d'lvoire/HIV-1 plasma viral load in tu 13328
losis patients, Abidjan, d'lvoire/HIV-1 plasma viral load and 13329
2000 - The situation in d'lvoire/Strategies of HIV/AIDS prev 13390
rise. An example of the d'lvoire/Profile of condom use by the 13466